CN117802127B - Salmonella phage lyase and gene, gene recombinant expression vector and application thereof - Google Patents
Salmonella phage lyase and gene, gene recombinant expression vector and application thereof Download PDFInfo
- Publication number
- CN117802127B CN117802127B CN202311849467.9A CN202311849467A CN117802127B CN 117802127 B CN117802127 B CN 117802127B CN 202311849467 A CN202311849467 A CN 202311849467A CN 117802127 B CN117802127 B CN 117802127B
- Authority
- CN
- China
- Prior art keywords
- salmonella
- lyase
- lys20059
- phage
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000607142 Salmonella Species 0.000 title claims abstract description 81
- 108090000856 Lyases Proteins 0.000 title claims abstract description 68
- 102000004317 Lyases Human genes 0.000 title claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 29
- 239000013604 expression vector Substances 0.000 title claims abstract description 13
- 238000003259 recombinant expression Methods 0.000 title claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 239000003124 biologic agent Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 230000009089 cytolysis Effects 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 238000001228 spectrum Methods 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 241001515965 unidentified phage Species 0.000 abstract description 3
- 238000003776 cleavage reaction Methods 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010039438 Salmonella Infections Diseases 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010039447 salmonellosis Diseases 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 230000002101 lytic effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 244000000007 bacterial human pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses salmonella phage lyase Lys20059, and a coding gene, an expression vector and application thereof. The amino acid sequence of the salmonella phage lyase Lys20059 is shown as SEQ ID NO.2, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 1. The salmonella phage lyase protein has a bacteriostasis ring on 42 strains of salmonella, has a salmonella lysis rate of 84%, shows a good salmonella lysis effect on salmonella, has a lysis effect on various salmonella serotypes, and has a wide lysis spectrum. The salmonella phage lyase Lys20059 has the effect of inhibiting the growth of salmonella, and has obvious high-concentration effect. The antibacterial agent is used for industrial production, aims at reducing cost, and has good antibacterial effect on salmonella under the action of a mixed preparation of a lower amount of bacteriophage and lyase.
Description
Technical Field
The invention relates to the technical field of bioengineering, in particular to a high-activity salmonella lyase, gene expression and application.
Background
Salmonella (Salmonella pullorum) belongs to the Enterobacteriaceae family, and gram-negative Enterobacter is the causative agent of salmonellosis. Among Salmonella are human pathogenic bacteria, veterinary pathogenic bacteria, and human and veterinary pathogenic bacteria. After salmonella infection, clinical symptoms such as gastrointestinal inflammation, fever, diarrhea, septicemia and the like generally occur. After infection with salmonella, animals may be affected in fertility and even have increased symptoms and mortality.
At present, antibiotics are mainly used in a method for treating salmonellosis, but due to unreasonable use of the antibiotics, the problems of bacterial multi-drug resistance, drug residues, food safety, unbalanced environmental flora and the like are caused, and the health of human beings and animals is seriously threatened.
Thus, in view of the reality of antibiotic resistance and policy requirements, there is a need to find effective methods for treating salmonellosis to alleviate or even solve the problems caused by antibiotic abuse.
In recent years, polypeptide antibacterial substances are becoming important points of research, because of their green and safe properties, and phage lytic enzymes are also widely used, among them, as antibacterial substances for polypeptides.
Phages replicate and reproduce bacteria as hosts, where mature particles are released by the synthesis of a class of proteolytic enzymes that lyse the bacterial cell walls. Such hydrolases are called phage lyases, also known as lyases, endolysins, lywallases, the molecular target of which is highly conserved peptidoglycan structures at the strain or genus level, which are critical for bacterial survival. During the co-evolution of phage and bacterial hosts for several billion years, lytic enzymes have also evolved and can attack molecular targets that are not easily altered by bacteria, and phages that do not attack these key targets will be naturally selected for elimination. Therefore, the case where bacteria develop resistance to lyase is extremely rare. The natural phage lyase can destroy bacterial biofilm, and has the advantages of green safety, difficult drug resistance and the like.
Therefore, providing a phage lyase and its use in the treatment of salmonellosis is a problem that those skilled in the art are urgent to address.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides salmonella phage lyase, a gene thereof, a gene recombination expression vector and application thereof.
The technical scheme of the invention is as follows:
In a first aspect, the application provides a coding gene of salmonella phage lyase Lys20059, wherein the nucleotide sequence of the coding gene of salmonella phage lyase Lys20059 is shown as SEQ ID NO. 1.
ATGTCAAACCGAAACATCAGTGACAACGGGTTACACTTCACCGCCGCGTTCGAGGGGTTCCGAGGAACCGCGTACAAGGCAACGAAGAACGAGAAGTACCTTACTATTGGTTATGGTCACTATGGTGCCGATGTGAAAGAAGGTCAGAAGATTACCGAAGGCCAGGGTCTTCTGCTGCTGCACAAGGATATGGCTAAGGCCGTAGCTGCGGTAGACACCGTTGCGCATCCGTCTCTAAATCAGTCACAGTTCGACGCCGTGTGTGACCTTGTGTATAACGCTGGTGCAGGTGTGATTGCCGCTTCTACCGGTACAGGTCAGGCGCTGCGCAAAGGCGATGCATCTACACTGCGTAATAAGTTAACTCAGTTCCATTATCAGAACGGCAAATCACTCCTCGGATTACGTCGTCGTGCCGCCGGTCGTGTTGCGCTGTTCGATGGCATGCTGTGGCAACAGGCCGAAGCTATCGGCCGTGGTGCAAAGTAG
Further, primers for amplifying the genes are as follows:
Lys-20059-F:CGGAATTCTCAAACCGAAACATCAGTG,SEQ ID NO.3;Lys-20059-R:CCCAAGCTTCTTTGCACCACGGCCGATAGCT,SEQ ID NO.4.
in a second aspect, the application provides a recombinant expression vector comprising a gene encoding the above-described salmonella phage lyase Lys 20059.
In a third aspect, the present application provides a host cell comprising a recombinant expression vector as described above.
In a fourth aspect, the invention also provides a salmonella phage lyase Lys20059, wherein the phage lyase Lys20059 is encoded by the encoding gene of the salmonella phage lyase Lys20059 in the first aspect, and the amino acid sequence of the salmonella phage lyase Lys20059 is shown in SEQ ID NO. 2.
MSNRNISDNGLHFTAAFEGFRGTAYKATKNEKYLTIGYGHYGADVKEGQKITEGQGLLLLHKDMAKAVAAVDTVAHPSLNQSQFDAVCDLVYNAGAGVIAASTGTGQALRKGDASTLRNKLTQFHYQNGKSLLGLRRRAAGRVALFDGMLWQQAEAIGRGAK
In a fifth aspect, based on the same invention, the invention also provides the use of the salmonella phage lyase according to the fourth aspect for inhibiting salmonella of different serotypes, in a biological formulation.
The invention has the following advantages:
1. The invention provides a salmonella phage lyase Lys20059 with an amino acid sequence shown in SEQ ID NO.2 and a nucleotide sequence of a coding gene shown in SEQ ID NO. 1. The phage lyase obtained by purification can well inhibit salmonella infection by constructing a recombinant vector and expressing in a genetically engineered strain escherichia coli BL21 (DE 3), and has potential clinical application value.
2. The salmonella phage lyase protein has a bacteriostasis ring for 42 strains of salmonella, has a salmonella lysis rate of 84%, shows a good salmonella lysis effect, has a salmonella lysis effect on various salmonella serotypes, and has a relatively wide lysis spectrum.
3. The salmonella phage lyase Lys20059 has the effect of inhibiting the growth of salmonella, and has obvious high-concentration effect. The antibacterial agent is used for industrial production, aims at reducing cost, and has good antibacterial effect on salmonella under the action of a mixed preparation of a lower amount of bacteriophage and lyase.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It is apparent that the drawings in the following description are only one embodiment of the present invention, and that other embodiments of the drawings may be derived from the drawings provided without inventive effort for a person skilled in the art.
Fig. 1: the phage lyase Lys-20059 fragment agarose electrophoresis detection result of the invention;
fig. 2: the phage lyase Lys-20059 expression vector agarose electrophoresis detection result;
Fig. 3: SDS-PAGE detection result of the phage lyase Lys-20059;
fig. 4: the invention relates to a bacteriostasis difference curve of phage lyase Lys-20059 and phage preparation combination on salmonella with different concentrations.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to fall within the scope of the invention. In the present invention, the equipment, materials, etc. used are commercially available or commonly used in the art, unless otherwise specified. The methods in the following examples are conventional in the art unless otherwise specified.
EXAMPLE 1 extraction of Salmonella phage genome
1.1 Salmonella phage RDP-SA-20059
Salmonella phage RDP-SA-20059 is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) with a preservation date of 2021 and 6 months and a preservation code of CGMCC No.22490.
1.2 Preparation of the genome of Salmonella phage RDP-SA-20059
Extracting salmonella phage RDP-SA-20059 by using a viral genome DNA extraction kit according to the method described in the application specification, and finally obtaining the extracted product, namely the genome DNA of the salmonella phage RDP-SA-20059, and storing at the temperature of minus 20 ℃ for standby.
Example 2 functional alignment search of salmonella phage RDP-SA-20059 lyase Gene
2.1 Phage genome sequencing
Phage whole genome sequencing and analysis: constructing a library by using an Illumina TruSeq TM Nano DNA SAMPLE PREP KIT method; the method comprises the following specific steps:
(1) Library construction with an initial amount of 1. Mu.g of phage genomic DNA;
(2) The Covaris M220 breaks the DNA to 300-500bp by ultrasound;
(3) Filling in the 3' end, adding A, and connecting index joint (TruSeq TM Nano DNA SAMPLE PREP KIT);
(4) Library enrichment, PCR amplification of 8 cycles;
(5) Recovering the target band (CERTIFIED LOW RANGE ULTRA AGAROSE) from the 2% agarose gel;
(6) Quantitative TBS380 (PicoGreen), mixing and loading according to the data proportion;
(7) carrying out bridge PCR amplification on cBot solid-phase carriers to generate clusters;
(8) The Illumina Hiseq sequencing platform was subjected to 2X 150bp sequencing.
2.2 Functional alignment analysis of the salmonella phage RDP-SA-20059 lyase Gene
By analyzing the sequencing annotation result, the predicted amino acid sequence with the function of cracking the cell wall is compared with public data, and is identified as salmonella phage lyase, which is named as Lys20059. The nucleotide sequence of the coding gene of the salmonella phage lyase Lys20059 is shown as SEQ ID NO. 1; the amino acid sequence of the salmonella phage lyase Lys20059 is shown as SEQ ID NO. 2.
Example 3: cloning of salmonella phage RDP-SA-20059 lyase gene, recombinant expression vector and construction of expression strain
3.1 PCR amplification of phage RDP-SA-20059 lyase Gene
The primers were designed according to the sequence of the lyase:
Lys-20059-F:CGGAATTCTCAAACCGAAACATCAGTG,SEQ ID NO.3;Lys-20059-R:CCCAAGCTTCTTTGCACCACGGCCGATAGCT,SEQ ID NO.4; The cleavage sites were EcoRI and HindIII, respectively.
Adding double enzyme cutting sites and protecting bases, taking phage genome as a template, and amplifying a lyase gene by using PCR (polymerase chain reaction), wherein the PCR procedure is shown in the following table 1; and (5) performing agarose gel electrophoresis detection on the PCR product.
Double digestion of the cleavage enzyme gene fragment (reaction system is shown in Table 2), phosphorylation and recovery of agarose gel fragment cleavage gel, and agarose gel electrophoresis detection of PCR products is carried out, and the results are shown in FIG. 1.
TABLE 1 PCR procedure for amplifying phage lyase genes
TABLE 2 double cleavage reaction System for PCR products
3.2 Construction of recombinant plasmid for phage lyase
(1) Preparation of Linear plasmids
The expression vector was constructed by selecting plasmid pET-28a, the vector was subjected to double digestion (Table 3), dephosphorylation (Table 4) and agarose gel fragment gel digestion recovery, and the plasmid enzyme digestion product was subjected to agarose gel electrophoresis detection.
Table 3 plasmid double enzyme cleavage reaction system
TABLE 4 phosphorylation reaction System of lyase fragments
(2) Construction of expression vectors
The cleavage enzyme fragment and the plasmid after cleavage were ligated, the ligation reaction system is shown in Table 5, and the construction result of the expression vector is shown in FIG. 2.
TABLE 5 ligation reaction System of cleavage enzyme fragments and restriction enzyme plasmids
3.3 Construction of Salmonella phage lyase Lys 20059-expressing Strain
1) Mu.l of the above ligation product was added to 50-100. Mu.l of competent cell BL21 (DE 3) and left to stand on ice for 30min. Then heat-shocking in a water bath at 42 ℃ for 90s, and placing the mixture on ice for 2-3min. 1ml of LB liquid medium was added thereto, and the culture was resumed by shaking at 220rpm at 37℃for 1 hour.
2) The bacterial liquid is coated on LB (antibiotic) plates, the plates are placed forward for about 2 hours at 37 ℃ to allow excessive liquid to permeate into the culture medium, and then the culture medium is inverted and cultured overnight.
3) Single colonies grown on LB+ resistant plates were picked and inoculated into 5-7ml of LB (antibiotic) liquid medium. Shaking table overnight shake culture at 37 ℃;
4) Plasmid extraction and sequencing were performed using the plasmid miniprep kit.
EXAMPLE 4 Induction, purification, preparation of recombinant lyase proteins
1) Transforming the expression plasmid into E.coli BL21 (DE 3), picking the transformant into 5mL of liquid LB medium added with ampicillin, and culturing at 37 ℃ with shaking overnight;
2) The overnight cultured bacterial liquid is transferred into LB liquid medium containing antibiotics according to the proportion of 1 percent, and is cultured at 200rpm and 37 ℃ until the OD600 is 0.6-0.8. 1mL of the bacterial liquid is centrifuged at 12,000rpm for 10min, 100. Mu.L of lysis buffer (50 mM Tris-HCl, 150mM NaCl, pH 8.0) is added to resuspend the bacterial cells, an equal volume of 2X protein loading buffer is added, and the bacterial cells are treated in a boiling water bath for 10min; meanwhile, adding IPTG to a bacterial liquid with the OD600 reaching 0.6-0.8 and the final concentration of 0.6-1.0mM into an inducer (isopropyl-beta-D-thiogalactoside), carrying out induced expression for 4 hours, taking 1mL of bacterial liquid, centrifuging to collect bacteria, adding a proper amount of lysis buffer to resuspend the bacteria, adding an equal volume of 2X protein loading buffer, and carrying out boiling water bath treatment for 10 minutes; SDS-PAGE detection proteins are soluble expressed;
3) Preparing a lyase protein expression thallus by the same method, adding a lysia buffer with the volume of 1/10 of the bacterial liquid, performing ultrasonic crushing, centrifuging at 12000rpm and 4 ℃ for 30min, and collecting a supernatant;
4) Balancing Ni column (His tag protein specific filler), mixing the supernatant sucked and collected by the filler, and incubating at 4 ℃ for 2h; adding the mixture of the supernatant and the filler into the empty column, and collecting the effluent supernatant for further detection;
5) Subjecting to column chromatography with a lysia buffer containing 10mM, 20mM, 50mM, 100mM, 250mM, 300mM, 400mM, and 500mM imidazole, eluting the hetero protein, collecting eluate to be detected, detecting protein concentration during detection, and detecting elution effects of imidazole at different concentrations to prepare lyase protein;
6) 500mM imidazole-eluted protein was collected, assayed for protein concentration, and subjected to thrombin treatment. The N-terminal 6 XHis tag was removed and the treatment conditions are shown in Table 6:
TABLE 6 thrombin treatment system and reaction conditions
7) Dialysis (dialysate: 50mM Tris-HCl, 150mM NaCl, 5% glycerol, pH 7.9) except imidazole: mixing the correct protein sample, adding into the treated dialysis bag, placing into dialysate, and treating at 4deg.C overnight; centrifuging at 12000rpm for 30min if precipitation occurs, and collecting supernatant; adding the dialyzed protein sample into an ultrafiltration tube, concentrating to a proper concentration, sub-packaging into small tubes, and preserving to-80 ℃;
SDS-PAGE detection of lyase Lys-20059 is shown in FIG. 3.
EXAMPLE 5 application of Salmonella phage lyase Lys20059
5.1 Antibacterial spectrum of Salmonella phage lyase Lys20059 against Salmonella
Salmonella 50 strains of different serotypes were selected for 17 Salmonella serotypes in total. The specific operation is as follows: spreading solid LB on a flat plate with the thickness of 3mm, placing a sterile oxford cup on a solid culture medium, mixing 100 mu l of salmonella bacteria liquid with 5ml of 0.7% LB semi-solid culture medium, pouring the mixture on the solid plate with the oxford cup, taking out the oxford cup by using sterile forceps after solidification, and forming a semi-solid culture medium hole. Filtering and sterilizing the prepared lyase protein solution, adding 20 mu l of protein solution into oxford cup hole seeds, culturing overnight at 37 ℃, and observing whether a bacteria inhibition zone exists.
The results are shown in Table 7, the cleavage enzyme protein has a bacteriostasis zone on 42 strains of salmonella, the cleavage rate on salmonella is 84%, the cleavage effect on salmonella is shown, the cleavage effect on salmonella of various serotypes is shown, and the cleavage spectrum is wide.
TABLE 7 Salmonella serotype 50 and cleavage of Salmonella by lytic enzymes
5.2 Use of Salmonella phage lyase Lys20059 in the preparation of a biological preparation for lysing Salmonella
Different concentrations (5, 10, 20, 30 and 40 mug) of lyase proteins are mixed with salmonella phage to form preparations, and bacteriostasis of the phage, the lyase and the mixed preparations of the phage and the lyase on salmonella is detected, wherein the phage performs bacteriostasis experiments with MOI of 1.0.
As shown in FIG. 4, the antibacterial effect of the low-concentration lyase on the phage is similar to that of the phage, and the antibacterial effect of the high-concentration lyase on salmonella is superior to that of the phage alone; the inhibition of salmonella growth by the experimental group of lytic enzymes and phage cocktails is superior to the inhibition of salmonella growth by phage or lytic enzymes alone.
In conclusion, the salmonella phage lyase Lys20059 has a growth inhibition effect on salmonella, and the high concentration effect is obvious. The antibacterial agent is used for industrial production, aims at reducing cost, and has good antibacterial effect on salmonella under the action of a mixed preparation of a lower amount of bacteriophage and lyase.
It will be understood that equivalents and modifications will occur to those skilled in the art in light of the present teachings and concepts, and all such modifications and substitutions are intended to be included within the scope of the present invention as defined in the accompanying claims.
Claims (6)
1. The coding gene of the salmonella phage lyase Lys20059 is characterized in that the nucleotide sequence of the coding gene of the salmonella phage lyase Lys20059 is shown as SEQ ID NO. 1.
2. A recombinant expression vector comprising a gene encoding the salmonella phage lyase Lys20059 of claim 1.
3. A host cell comprising the recombinant expression vector of claim 2.
4. A salmonella phage lyase Lys20059 is characterized in that phage lyase Lys20059 is encoded by the encoding gene of salmonella phage lyase Lys20059 of claim 1, and the amino acid sequence of salmonella phage lyase Lys20059 is shown in SEQ ID NO. 2.
5. Use of salmonella phage lyase Lys20059 of claim 4 for inhibiting salmonella of different serotypes, wherein the use is not diagnostic, therapeutic or prophylactic in relation to a disease.
6. A biological agent, wherein the active ingredient of the biological agent comprises salmonella phage lyase Lys20059 of claim 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311849467.9A CN117802127B (en) | 2023-12-28 | 2023-12-28 | Salmonella phage lyase and gene, gene recombinant expression vector and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311849467.9A CN117802127B (en) | 2023-12-28 | 2023-12-28 | Salmonella phage lyase and gene, gene recombinant expression vector and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117802127A CN117802127A (en) | 2024-04-02 |
CN117802127B true CN117802127B (en) | 2024-07-05 |
Family
ID=90431567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311849467.9A Active CN117802127B (en) | 2023-12-28 | 2023-12-28 | Salmonella phage lyase and gene, gene recombinant expression vector and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117802127B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108486089A (en) * | 2018-04-16 | 2018-09-04 | 中国水产科学研究院黄海水产研究所 | Derived from the wide range lyases and its antibacterial applications of salmonella bacteriophage |
CN110656093A (en) * | 2019-10-12 | 2020-01-07 | 山东省农业科学院畜牧兽医研究所 | Novel salmonella phage library and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003240505A1 (en) * | 2002-06-05 | 2003-12-22 | Iowa State University Research Foundation, Inc. | Bacteriophage and enzymes lytic to salmonellae |
KR101449417B1 (en) * | 2012-06-20 | 2014-10-27 | 한국외국어대학교 연구산학협력단 | Bacteriophage of Salmonella enterica and uses thereof |
CN112063594B (en) * | 2020-09-24 | 2022-02-11 | 瑞科盟(青岛)生物工程有限公司 | High-temperature-resistant salmonella bacteriophage RDP-SA-18056 and preparation process of microcapsules thereof |
CN113151194B (en) * | 2021-05-18 | 2022-05-31 | 瑞科盟(青岛)生物工程有限公司 | Salmonella bacteriophage resistant to antiviral drugs and application thereof |
-
2023
- 2023-12-28 CN CN202311849467.9A patent/CN117802127B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108486089A (en) * | 2018-04-16 | 2018-09-04 | 中国水产科学研究院黄海水产研究所 | Derived from the wide range lyases and its antibacterial applications of salmonella bacteriophage |
CN110656093A (en) * | 2019-10-12 | 2020-01-07 | 山东省农业科学院畜牧兽医研究所 | Novel salmonella phage library and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN117802127A (en) | 2024-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gorlas et al. | TPV1, the first virus isolated from the hyperthermophilic genus Thermococcus | |
Gaudin et al. | Extracellular membrane vesicles harbouring viral genomes | |
Lavigne et al. | The genome of bacteriophage φKMV, a T7-like virus infecting Pseudomonas aeruginosa | |
Petrov et al. | Plasticity of the gene functions for DNA replication in the T4-like phages | |
Yuzenkova et al. | Genome of Xanthomonas oryzae bacteriophage Xp10: an odd T-odd phage | |
CN112143747B (en) | Phage lyase, gene thereof, gene recombination expression vector and application | |
Cazares et al. | Core and accessory genome architecture in a group of Pseudomonas aeruginosa Mu-like phages | |
KR101725570B1 (en) | Podoviridae Bacteriophage Having Killing Activity Specific to gram negative bacteria | |
CN111690054B (en) | Pinctada martensii Kunitz type serine protease inhibitor gene, encoded protein and application | |
CN113549610B (en) | Antibacterial peptide P104 with broad-spectrum lytic activity, lyase LysP53 and application thereof | |
CN111304181B (en) | Genetically engineered vibrio parahemolyticus phage lyase and preparation method and application thereof | |
CN106854247A (en) | A kind of preparation method of the bacterial virus catenase that can crack Escherichia coli and salmonella | |
CN107828769B (en) | Heat-resistant lyase MMPpgh and polynucleotide for encoding same | |
Yoshida-Takashima et al. | Genome sequence of a novel deep-sea vent epsilonproteobacterial phage provides new insight into the co-evolution of Epsilonproteobacteria and their phages | |
CN112852794B (en) | Clostridium perfringens bacteriophage lyase and application thereof | |
KR20180004584A (en) | Bacteriophage JBP901 belonging to subfamily Spounavirinae of family Myoviridae and its use | |
CN111378638A (en) | Helicobacter pylori phage lyase and preparation method thereof | |
CN117802127B (en) | Salmonella phage lyase and gene, gene recombinant expression vector and application thereof | |
CN111856005B (en) | Application of mycoplasma bovis secretory protein MbovP280 | |
KR101601912B1 (en) | 14 New bacteriophage Ep14 | |
Lee et al. | A novel lysozyme from Xanthomonas oryzae phage ϕXo411 active against Xanthomonas and Stenotrophomonas | |
CN114292836A (en) | Lyase of endoproteolyticenza salmonella bacteriophage, encoding gene thereof, preparation method and application thereof | |
CN111909917B (en) | Endolysin Lysmeta1 and coding gene and application thereof | |
JP2021185912A (en) | Novel chitosanase chi1 as well as coding gene and application thereof | |
CN117660413B (en) | Endolysin Lys009, engineering modification and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |